| Website | diobex.com |
| Category | BioTech |
| Phone | 415-551-0400 |
| Employees | |
| Founded | 2003 |
| Description | biotechnology company |
| TOTAL | $31.1M |
| FUNDING TOTAL | $31.1M |
| Venture Round, 9/05 Domain Associates FirstMark Capital Sofinnova Ventures | $7.08M |
| Series B, 4/07 Inventages Venture Capital Investment Inc. Mitsui Ventures Pac-Link Domain Associates Pequot Capital Sofinnova Ventures | $24M |
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.
